Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business
Teleflex (NYSE:TFX) has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million in cash. The acquisition significantly enhances Teleflex's global presence in the catheterization laboratory and establishes its footprint in the growing peripheral intervention market.
The acquired portfolio includes key products for coronary and peripheral interventions such as the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal also includes Freesolve, a CE-marked sirolimus-eluting Resorbable Metallic Scaffold technology.
Financially, the acquired products are expected to generate €177 million ($204 million) in revenues for the second half of 2025, with €91 million ($105 million) projected for Q4 2025. From 2026, the business is anticipated to deliver annual constant currency revenue growth of 6% or better. The transaction is expected to be $0.10 accretive to Teleflex's adjusted earnings per share in the first year.
Teleflex (NYSE:TFX) ha completato l'acquisizione del settore Vascular Intervention di BIOTRONIK per 760 milioni di euro in contanti. Questa acquisizione rafforza significativamente la presenza globale di Teleflex nei laboratori di cateterizzazione e consolida la sua posizione nel mercato in crescita delle interventi periferici.
Il portafoglio acquisito comprende prodotti chiave per interventi coronarici e periferici come il Pantera Lux Catetere a Palloncino Rivestito con Farmaco, il PK Papyrus Stent Coronario Coperto e l'Orsiro Mission Stent a Rilascio di Farmaco. L'accordo include anche Freesolve, una tecnologia CE-marked di scaffold metallico riassorbibile a rilascio di sirolimus.
Dal punto di vista finanziario, si prevede che i prodotti acquisiti genereranno 177 milioni di euro (204 milioni di dollari) di ricavi nella seconda metà del 2025, con 91 milioni di euro (105 milioni di dollari) stimati per il quarto trimestre 2025. A partire dal 2026, si prevede una crescita annua dei ricavi a valuta costante del 6% o superiore. La transazione dovrebbe aumentare l'utile per azione rettificato di Teleflex di 0,10 dollari nel primo anno.
Teleflex (NYSE:TFX) ha completado la adquisición del negocio de Intervención Vascular de BIOTRONIK por 760 millones de euros en efectivo. Esta adquisición mejora significativamente la presencia global de Teleflex en los laboratorios de cateterismo y establece su posición en el creciente mercado de intervenciones periféricas.
El portafolio adquirido incluye productos clave para intervenciones coronarias y periféricas como el Catéter con Balón Recubierto con Fármaco Pantera Lux, el Stent Coronario Cubierto PK Papyrus y el Stent Farmacológico Orsiro Mission. El acuerdo también incluye Freesolve, una tecnología de andamio metálico reabsorbible con liberación de sirolimus con marcado CE.
Desde el punto de vista financiero, se espera que los productos adquiridos generen 177 millones de euros (204 millones de dólares) en ingresos durante la segunda mitad de 2025, con 91 millones de euros (105 millones de dólares) proyectados para el cuarto trimestre de 2025. A partir de 2026, se anticipa un crecimiento anual de ingresos en moneda constante del 6% o más. Se espera que la transacción incremente las ganancias ajustadas por acción de Teleflex en 0,10 dólares en el primer año.
Teleflex (NYSE:TFX)는 BIOTRONIK의 혈관 중재 사업부를 7억 6천만 유로 현금으로 인수하는 절차를 완료했습니다. 이번 인수로 Teleflex는 전 세계 카테터실에서의 입지를 크게 강화하고 성장 중인 말초 중재 시장에 진출하게 되었습니다.
인수한 포트폴리오에는 Pantera Lux 약물 코팅 풍선 카테터, PK Papyrus 덮개형 관상동맥 스텐트, Orsiro Mission 약물 방출 스텐트 등 관상동맥 및 말초 중재용 주요 제품들이 포함되어 있습니다. 또한 이번 거래에는 CE 인증을 받은 sirolimus 방출형 흡수성 금속 스캐폴드 기술인 Freesolve도 포함되어 있습니다.
재무적으로, 인수한 제품들은 2025년 하반기에 1억 7,700만 유로(2억 400만 달러)의 매출을 창출할 것으로 예상되며, 2025년 4분기에는 9,100만 유로(1억 500만 달러)가 예상됩니다. 2026년부터는 연간 환율 고정 기준 매출이 6% 이상 성장할 것으로 기대됩니다. 이번 거래는 첫 해에 Teleflex의 조정 주당순이익을 0.10달러 증가시킬 것으로 전망됩니다.
Teleflex (NYSE:TFX) a finalisé l'acquisition de l'activité Intervention Vasculaire de BIOTRONIK pour 760 millions d'euros en numéraire. Cette acquisition renforce considérablement la présence mondiale de Teleflex dans les laboratoires de cathétérisme et établit sa position sur le marché en croissance des interventions périphériques.
Le portefeuille acquis comprend des produits clés pour les interventions coronaires et périphériques tels que le cathéter à ballonnet enduit de médicament Pantera Lux, le stent coronaire couvert PK Papyrus et le stent à élution médicamenteuse Orsiro Mission. L'accord inclut également Freesolve, une technologie de support métallique résorbable à élution de sirolimus certifiée CE.
Sur le plan financier, les produits acquis devraient générer 177 millions d'euros (204 millions de dollars) de revenus au second semestre 2025, avec 91 millions d'euros (105 millions de dollars) prévus pour le quatrième trimestre 2025. À partir de 2026, une croissance annuelle des revenus en devises constantes de 6 % ou plus est anticipée. La transaction devrait augmenter le bénéfice ajusté par action de Teleflex de 0,10 dollar dès la première année.
Teleflex (NYSE:TFX) hat die Übernahme des Geschäftsbereichs Vascular Intervention von BIOTRONIK für 760 Millionen Euro in bar abgeschlossen. Die Akquisition stärkt Teleflex' globale Präsenz im Katheterlabor erheblich und etabliert das Unternehmen im wachsenden Markt für periphere Interventionen.
Das erworbene Portfolio umfasst wichtige Produkte für koronare und periphere Interventionen wie den Pantera Lux Drug-Coated Balloon Katheter, den PK Papyrus Covered Coronary Stent und den Orsiro Mission Drug Eluting Stent. Der Deal beinhaltet außerdem Freesolve, eine CE-zertifizierte sirolimus-freisetzende resorbierbare Metallgerüst-Technologie.
Finanziell wird erwartet, dass die übernommenen Produkte im zweiten Halbjahr 2025 177 Millionen Euro (204 Millionen US-Dollar) Umsatz erzielen, davon 91 Millionen Euro (105 Millionen US-Dollar) im vierten Quartal 2025. Ab 2026 wird ein jährliches Umsatzwachstum in konstanter Währung von 6 % oder mehr erwartet. Die Transaktion soll das bereinigte Ergebnis je Aktie von Teleflex im ersten Jahr um 0,10 US-Dollar erhöhen.
- Acquisition expands Teleflex's presence in the growing peripheral intervention market
- Expected to generate €177 million ($204 million) in revenues for H2 2025
- Projected 6% or better annual constant currency revenue growth from 2026
- Transaction to be $0.10 accretive to adjusted EPS in first year
- Adds comprehensive portfolio of therapeutic products for coronary and peripheral interventions
- Acquisition completed earlier than expected
- Includes CE-marked Freesolve technology with positive clinical trial results
- Significant cash outlay of €760 million for the acquisition
- Integration costs and non-recurring purchase accounting items will impact initial earnings
Insights
Teleflex's €760M acquisition of BIOTRONIK's vascular business expands cath lab presence, adds innovative products, and immediately boosts earnings.
Teleflex has completed its previously announced €760 million acquisition of BIOTRONIK's Vascular Intervention business ahead of schedule, creating immediate strategic and financial benefits. This transaction strategically transforms Teleflex's position in the interventional space by adding a comprehensive portfolio of coronary and peripheral vascular products while establishing the company's footprint in the fast-growing peripheral intervention market.
The acquisition brings several high-value differentiated products to Teleflex's portfolio, including the Pantera Lux Drug-Coated Balloon, PK Papyrus Covered Coronary Stent, Orsiro Mission Drug Eluting Stent, and peripheral intervention products. Particularly noteworthy is gaining access to Freesolve, a sirolimus-eluting Resorbable Metallic Scaffold technology that received CE Mark in February 2024, positioning Teleflex at the forefront of the trend toward less permanent hardware in vascular interventions.
The financial impact is immediately positive, with the acquisition expected to generate
WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication.
On February 27, 2025, Teleflex announced its entry into a definitive agreement to acquire substantially all of BIOTRONIK’s Vascular Intervention business. Under the terms of the agreement, Teleflex acquired the Vascular Intervention business for a cash payment of
“We are pleased to announce the completion of the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK earlier than expected” said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care. We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market. The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies. We will provide additional details on our second quarter earnings conference call.”
The acquired Vascular Intervention business consists of a comprehensive and differentiated portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, key products include the Pantera™ Lux™ Drug-Coated Balloon Catheter, the novel PK Papyrus™ Covered Coronary Stent for acute coronary artery perforations, and the Orsiro™ Mission Drug Eluting Stent, an ultrathin drug-eluting stent with differentiated clinical features. For peripheral interventions, the portfolio includes the Passeo™-18 Lux™ Peripheral Drug-Coated Balloon Catheter, Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent, the Pulsar™-18 T3 Self-Expanding 4F Stent, and the Oscar™ peripheral multifunctional catheter system.
The acquisition of the Vascular Intervention business will also allow Teleflex the opportunity to invest in and expand the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold (RMS) technology, including plans to initiate a U.S. pivotal study. Freesolve™, which received its CE Mark in February 2024, is indicated in CE-mark accepting countries for de novo coronary artery lesions. The combination of temporary scaffolding with drug delivery is anticipated to address the current trend in interventional coronary and endovascular procedures toward leaving behind less permanent hardware. As demonstrated in the BIOMAG-I study, Freesolve™ RMS demonstrated resorption after 12 months, a target lesion failure rate comparable to contemporary drug-eluting stents, and no definite or probable scaffold thrombosis.1,2 The European pivotal BIOMAG-II study is now enrolling.
Vascular Intervention Acquisition Financial Outlook
Given the earlier than expected completion of the Vascular Intervention acquisition, we now expect the acquired products to generate revenues of
Excluding non-recurring purchase accounting items and other acquisition and integration related costs, the transaction is still expected to be approximately
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Not all products may be available in all countries. The above-referenced drug-coated devices are not available in the United States and Japan.
References:
- Seguchi M, Aytekin A, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Waksman R, Garcia-Garcia HM, Joner M. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study. EuroIntervention. 2024 Sep 16;20(18):e1173-e1183. doi: 10.4244/EIJ-D-24-00055. PMID: 39279514; PMCID: PMC11384225. The study was sponsored by BIOTRONIK. M. Seguchi, M. Haude, J.F. Iglesias, J. Bennett, G.G. Toth, M. Wiemer, G. Olivecrona, R. Waksman, H.M. Garcia-Garcia, and M. Joner are paid consultants of BIOTRONIK.
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Garcia HM, Waksman R. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023 Aug 7;19(5):e414-e422. doi: 10.4244/EIJ-D-23-00326. PMID: 37334655; PMCID: PMC10397670.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements about our acquisition of the Vascular Intervention business, our and the Vascular Intervention business’s commercialized and pipeline products, and the Vascular Intervention business’s technology platform, including, in each case, their potential benefits, anticipated revenue contribution, and anticipated adjusted earnings per share accretion. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; customer and shareholder reaction to the transaction; risks associated with the completed financing of the transaction; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; unknown liabilities; the risk of regulatory actions related to the acquisition; changes in general and international economic conditions, including fluctuations in foreign currency exchange rates; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024.
CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Titan SGS, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Other names are the trademarks of their respective owners. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative.
© 2025 Teleflex Incorporated. All rights reserved.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
FAQ
How much did Teleflex (TFX) pay for BIOTRONIK's Vascular Intervention business?
What revenue is expected from the BIOTRONIK Vascular Intervention acquisition in 2025?
What are the key products included in Teleflex's acquisition of BIOTRONIK's Vascular business?
How will the BIOTRONIK acquisition affect Teleflex's earnings?
What is the projected growth rate for the acquired BIOTRONIK business?
